Our findings expand the genotypic spectrum of DYNC1H1-related epilepsy and suggested KD might be an optimized treatment for drug-resistant DEE, providing valuable clinical insights for the management of these patients. Here, DYNC1H1 is linked to developmental and epileptic encephalopathy.